Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.
Frontiers in oncology（2022）
Abstract
TMB-high advanced gastric cancer patients accounted for around one-sixth and had a poorer prognosis than TMB-low patients when treated with first-line chemotherapy. The potential mechanism might be the downregulated metabolic activity in TMB-high patients.
MoreTranslated text
Key words
biomarker,chemotherapy,gastric cancer,mechanism,prognostic value,tumor mutation burden
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined